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Abstract
Background: The inducible cyclic adenosine monophosphate (cAMP) early repressor (ICER) is highly expressed in the central
nervous system and functions as a repressor of cAMP response element-binding protein (CREB) transcription. The present
study sought to clarify the role of ICER in the effects of methamphetamine (METH).
Methods and Findings: We tested METH-induced locomotor sensitization in wildtype mice, ICER knockout mice, and ICER I-
overexpressing mice. Both ICER wildtype mice and knockout mice displayed increased locomotor activity after continuous
injections of METH. However, ICER knockout mice displayed a tendency toward higher locomotor activity compared with
wildtype mice, although no significant difference was observed between the two genotypes. Moreover, compared with
wildtype mice, ICER I-overexpressing mice displayed a significant decrease in METH-induced locomotor sensitization.
Furthermore, Western blot analysis and quantitative real-time reverse transcription polymerase chain reaction
demonstrated that ICER overexpression abolished the METH-induced increase in CREB expression and repressed cocaine-
and amphetamine-regulated transcript (CART) and prodynorphin (Pdyn) expression in mice. The decreased CART and Pdyn
mRNA expression levels in vivo may underlie the inhibitory role of ICER in METH-induced locomotor sensitization.
Conclusions: Our data suggest that ICER plays an inhibitory role in METH-induced locomotor sensitization.
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Introduction
The inducible cyclic adenosine monophosphate (cAMP) early
repressor (ICER) is the collective name for a group of proteins
produced from the cAMP response element modulator (CREM)/
ICER gene driven by the P2 internal promoter located in an intron
of the CREM gene [1]. Lacking the CREM N-terminus, ICER only
contains two DNA binding domains (DBD I and DBD II) and lacks
the activation and kinase-inducible domains. Consequently, ICER
functions as an endogenous repressor of transcription of several
cAMP response element (CRE)-containing genes [1–3]. The P2
promoter of the ICER gene contains two pairs of CRE sequences.
The phosphorylated CRE-binding protein (CREB) can induce
transcription of the ICER gene from the P2 promoter. The
increased ICER competes with CREB in binding with the CRE
sequence, blocking transcription from CRE-containing promoters,
including ICER’s own promoter, and functioning as a potent
endogenous CREB antagonist [1,4].
Four ICER isoforms have been identified: ICER I, ICER Ic,
ICER II, and ICER IIc. ICER I mRNA contains DBD I and DBD
II, but DBD II is absent in the ICER I protein because a stop codon
exists at the end of DBD I. The ICER II isoform contains only DBD
II. ICER Ic and ICER IIc are characterized by a deficiency of exon
c from ICER I and ICER II, respectively [4].
Numerous reports have shown that CREB in the nucleus
accumbens (NAc) is associated with responses to drugs of abuse
and emotional responses. Chronic drug administration increases
levels of CREB immunoreactivity and CRE-binding activity [5–6].
Overexpression ofCREBbyintroducing herpes simplex virus-CREB
into the NAc decreases behavioral responses to drug administration,
whereasblockade ofCREBtranscription via introducing adominant-
negative CREB mutant or via genetic knockout increases behavioral
responses to drug administration [7–10]. However, other studies
showed that genetic ablation of CREB did not affect the rewarding
effects of psychostimulants [11–13], indicating that the role of CREB
in drug-induced responses is debatable. Recent findings suggest that
ICER mRNA expression was threefold higher in the striatum after
amphetamine injection [14], suggesting that the endogenous
functional CREB antagonist ICER may participate in the mecha-
nisms that underlie the effects of drugs of abuse.
The prodynorphin (Pdyn) peptide is an endogenous ligand of
the k opioid receptor. Cocaine- and amphetamine-regulated
transcript (CART) was first sequenced as a peptide with unknown
function [15], and previous studies revealed that the CART
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drug reward, including the NAc and ventral tegmental area (VTA)
[16–17]. Both CART and Pdyn play roles as psychostimulant
neuromodulators [8,18–20]. CART and Pdyn mRNA are
suggested to be CRE-mediated transcripts regulated by CREB in
vitro and in vivo [8,21–23].
Kojima et al. [24] generated two types of ICER mutant mice—
ICER knockout mice and ICER-overexpressing mice—and
suggested a negative role for ICER in regulating long-term fear
memory and kindling epileptogenesis. The present study used two
types of transgenic mice with opposite genetic alterations of ICER
gene expression (i.e., ICER knockout and ICER I-overexpressing
mice) and investigated the role of ICER in methamphetamine
(METH)-induced locomotor sensitization. Locomotor sensitization
is characterized by the progressive enhancement of locomotor
activity after repeated psychostimulant exposure [25–26]. The
augmentation of this behavioral response can be maintained for
several months after the cessation of drug treatment [27]. We
observed an inhibitory effect of ICER on METH-induced
locomotor sensitization. To identify the downstream components
of ICER-mediated gene transcription in vivo and provide a possible
mechanism that contributes to the inhibitory role of ICER in
METH-induced locomotor sensitization, we determined METH-
induced CREB and phosphorylated CREB (pCREB) levels using
Western blot analysis and further determined CART and Pdyn
mRNA expression levels in the striatum (caudate putamen [CPu],
which mediates locomotor activity) but not in the NAc (which
mainly mediates the rewarding effects of drugs of abuse) in ICER
I-overexpressing mice and their littermates using real-time reverse
transcription polymerase chain reaction (RT-PCR).
Results
METH-induced locomotor sensitization in ICER I-
overexpressing mice
Consistent with a previous study [28], on Day 1, the initially
elevated levels of locomotor activity in wildtype mice were reduced to
near-zero levels after 180 min habituation. ICER I-overexpressing
mice displayed a similar pattern of locomotor activity as wildtype
mice (Fig. 1a). No significant difference in baseline locomotion was
observed between genotypes (n=7 for wildtype mice; n=9forICER
I-overexpressing mice; F1,16=0.49, p=0.49; Fig. 1a). On Day 20,
ICER I-overexpressing mice displayed decreased levels of spontane-
ous locomotor activity during the 180 min habituation period
compared with wildtype mice (F1,14=9.934, p=0.007; Fig. 1b). After
a METH injection (1 mg/kg), a significant difference was observed
between the two genotypes (F1,14=14.566, p=0.0019; Fig. 1b).
Repeated administration of METH (1 mg/kg) on Days 1, 3, 5, 7, 9,
11, 13, and 20 significantly increased locomotor activity in both
wildtype and ICER I-overexpressing mice (Fig. 1c). A two-way,
mixed-design analysis of variance (ANOVA; Genotype6Day)
revealed a significant effect of Day (F7,98=19.13, p,0.0001),
indicating the presence of METH-induced locomotor sensitization.
METH-induced locomotor sensitization in ICER I-overexpressing
mice significantly decreased compared with wildtype mice
(F1,14=12.54, p=0.0033; Fig. 1c), and a significant Genotype6Day
interaction was observed (F7,98=6.52,p,0.0001; Fig. 1c). From Day
5, locomotor activity in ICER I-overexpressing mice was significantly
lower than in wildtype mice (Student’s t-test).
METH-induced locomotor sensitization in ICER knockout
mice
On Day 1, the levels of locomotor activity in wildtype and ICER
knockout mice were reduced to near-zero after 180 min habitua-
Figure 1. Spontaneous and METH-stimulated locomotor activ-
ity in wildtype mice (WT) and ICER I-overexpressing mice (Tg).
METH (1 mg/kg) was administered once per day on Days 1, 3, 5, 7, 9, 13,
and 20 in WT (n=7) and Tg (n=9) mice. a. Time-course of spontaneous
locomotor activity before and after METH administration on Day 1. The
data are expressed as mean 6 SEM beam breaks in 5 min bins. The
arrow indicates the start of a METH injection. b. Time-course of
spontaneous locomotor activity before and after METH administration
on Day 20. The data are expressed as mean 6 SEM beam breaks in
5 min bins. The arrow indicates the start of a METH injection. c. METH-
induced locomotor sensitization. The data are expressed as mean 6
SEM beam breaks during the 60 min period after METH injection (1 mg/
kg) on Days 1, 3, 5, 7, 9, 13, and 20. *p,0.05, **p,0.01, ***p,0.001,
significant difference in locomotor activity scores between WT and Tg
mice.
doi:10.1371/journal.pone.0021637.g001
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between genotypes (n=13 for both wildtype and knockout mice;
F1,24=0.27, p=0.61; Fig. 2a). After repeated procedures on Days 1,
3, 5, 7, 9, 11, and 13 and a 7 day drug-free period, on Day 20, the
levels of locomotor activity in the two genotypes were reduced but
did not reach near-zero levels after 180 min habituation, which
might have beencausedby the repeated METHadministration. No
significant difference was detected between the two genotypes
during the habituation period (F1,24=2.731, p=0.12; Fig. 2b). After
a METH injection (1 mg/kg), locomotor activity in both genotypes
increased significantly. No significant difference was observed
between the two genotypes (F1,24=2.071, p=0.16; Fig. 2b).
Repeated administration of METH (1 mg/kg) significantly in-
creased locomotor activity in both wildtype and ICER knockout
mice (Fig. 2c). A two-way, mixed-design ANOVA (Genotype6Day)
revealed a significant effect of Day (F7,168=25.88, p,0.0001),
indicating the presence of METH-induced locomotor sensitization.
ICER knockout mice showed a tendency toward higher locomotor
activity compared with their wildtype littermates (F1,24=2.96,
p=0.098). ICER knockout mice displayed greater locomotor
activity on Day 3 and Day 11 compared with wildtype mice
(p,0.05; Tukey-Kramer post hoc test). No significant Genotype6
Day interaction was observed (F7,168=0.62, p=0.74).
METH-induced CREB expression and phosphorylation in
the CPu was abolished in ICER I-overexpressing mice
Two-way ANOVA revealed marginal differences between geno-
types in CREB and pCREB protein levels in the CPu after repeated
METH treatment (CREB: F1,40=3.76, p=0.06; pCREB: F1,40=3.51,
p=0.07). No significant difference in the effect of METH was found
(CREB: F3,40=1.28,p=0.29; pCREB: F3,40=1.38, p=0.26), and no
Genotype6METH interaction was observed (CREB: F3,40=1.90,
p=0.15; pCREB: F3,40=1.79, p=0.16). The Dunnett post hoc test
revealed that repeated METH/saline challenge significantly increased
C R E Bp r o t e i nl e v e l si nw i l d t y p em i c ec o m p a r e dw i t ht h es a l i n eg r o u p
(n=6pergroup,p,0.05; Fig. 3a). The level of activated CREB protein
(pCREB) in the repeated METH/saline challenge group also
significantly increased in wildtype mice (n=6 per group, p,0.05,
Dunnett post hoc test; Fig. 3b). However, the levels of CREB and
pCREB protein were not significantly altered after repeated METH
injection in ICER I-overexpressing mice (Fig. 3).
ICER overexpression significantly reduced CART and
Pdyn mRNA expression in the CPu
To identify the downstream components of CRE-mediated gene
transcription that contribute to reduced METH-induced locomotor
sensitization in ICER I-overexpressing mice, real-time RT-PCR
was conducted. First, ICER mRNA levels were evaluated using
ICER-specific primers. Significant effects were found for Genotype
(F1,24=1850.5, p,0.001, two-way ANOVA; Fig. 4a). However,
METH injection did not significantly affect ICER mRNA levels in
wildtype mice (n=4 per group, p.0.05, Dunnett post hoc test).
Furthermore, we evaluated CART and Pdyn mRNA levels because
they are suggested to be CRE-mediated transcripts and psycho-
stimulant neuromodulators. Although METH did not alter CART
or Pdyn mRNA expression in ICER I-overexpressing mice and
their littermates (CART: F3,24=0.31, p=0.81; Pdyn: F3,24=0.38,
p=0.77; two-way ANOVA), CART and Pdyn mRNA expression
levels were significantly reduced in ICER I-overexpressing mice
compared with their littermates (CART: F1,24=17.25, p,0.01;
Pdyn: F1,24=12.21, p,0.01; two-way ANOVA; Fig. 4b, c). No
significant Genotype6METH interaction was observed (CART:
F3,24=0.21, p=0.89; Pdyn: F3,24=0.17, p=0.92).
Figure 2. Spontaneous and METH-stimulated locomotor activ-
ity in wildtype (WT) and ICER knockout (KO) mice. METH (1 mg/
kg) was administered once per day on Days 1, 3, 5, 7, 9, 13, and 20 in WT
(n=13) and ICER-KO (n=13) mice. a. ime-course of spontaneous
locomotor activity before and after METH administration on Day 1. The
data are expressed as mean 6 SEM beam breaks in 5 min bins. The
arrow indicates the start of a METH injection. b. Time-course of
spontaneous locomotor activity before and after METH administration
on Day 20. The data are expressed as mean 6 SEM beam breaks in
5 min bins. The arrow indicates the start of a METH injection. c. METH-
induced locomotor sensitization. The data are expressed as mean 6
SEM beam breaks during the 60 min period after METH injection (1 mg/
kg). *p,0.05, significant difference in locomotor activity scores
between WT and KO mice.
doi:10.1371/journal.pone.0021637.g002
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The present study investigated the role of ICER in long-lasting
METH-induced behavioral alterations by evaluating METH-
induced locomotor sensitization in ICER knockout and ICER-
overexpressing mice. The major findings of the present study were
that ICER I overexpression significantly inhibited METH-induced
locomotor sensitization and blocked METH-induced increases in
CREB and pCREB protein levels. Additionally, CART and Pdyn
mRNA expression levels in the CPu were significantly reduced in
ICER-overexpressing mice. ICER knockout mice displayed a
tendency toward higher activity after repeated METH adminis-
tration compared with their wildtype littermates, although no
significant difference was detected between ICER knockout mice
and their wildtype littermates. Considering the negative regulatory
role of CREB in the effects of psychostimulants [18,29–30], the
reduction in METH-induced locomotor sensitization in ICER-
overexpressing mice may be attributable to reduced CART and
Pdyn mRNA expression, rather than attributable to increased
CREB and pCREB protein levels.
Inhibitory role of ICER in METH-induced locomotor
sensitization
Although the mechanisms that underlie locomotor sensitization
are not fully understood, it is hypothesized to reflect neuronal
adaptations in several brain regions, including in dopamine
neurons and the CPu [25]. In the present study, ICER I-
overexpressing mice exhibited a significant reduction in METH-
induced locomotor sensitization compared with wildtype mice
(Fig. 1c), whereas ICER knockout mice showed a minimal
enhancement of METH-induced locomotor sensitization com-
pared with wildtype mice (Fig. 2c). Altogether, these results suggest
that ICER plays an inhibitory role in METH-induced locomotor
sensitization.
CREB overexpression in the NAc reportedly decreased
cocaine- and morphine-induced conditioned place preference
(CPP), and decreased CREB in the NAc increased cocaine- and
morphine-induced CPP [7–8], suggesting that increased CREB
in the NAc has an inhibitory effect on the induction of CPP.
However, recent studies have reported conflicting results, in
which genetic ablation of CREB did not affect the rewarding
properties of psychostimulants [11–13]. Similarly, some studies
demonstrated an inhibitory role of CREB in cocaine-induced
sensitization [31–32], whereas other studies with CREB mutant
mice suggested either minor effects [33] or no effects [11] of
CREB on cocaine-induced sensitization. In the present study,
overexpression of the endogenous CREB repressor ICER
inhibited METH-induced locomotor sensitization. Thus, the
inhibitory effect of CREB on the psychostimulant-induced
response is debatable. A possible explanation for these discrepant
results may include the different gene manipulations (i.e.,
forebrain- or NAc-specific gene manipulation), different drug
types (i.e., METH or cocaine/morphine), and different targeted
genes (i.e., ICER or CREB).
Enhanced pCREB in the striatum is a molecular marker of
neuroadaptations to chronic psychostimulant-induced plasticity
[8,21,29,34–35]. In the present study, both CREB and pCREB
levels increased in wildtype mice after repeated METH injection.
The increased CREB and subsequent pCREB induced by
repeated METH might homeostatically oppose the effect of
METH [29]. However, the repeated METH-induced increases in
CREB levels were blocked by ICER I overexpression, suggesting
that the negative regulation of the CREB pathway was absent in
ICER I-overexpressing mice. Therefore, the CREB pathway may
not be involved in the reduced locomotor sensitization observed in
ICER I-overexpressing mice. Additionally, ICER expression was
60-fold greater in ICER overexpressing mice than in wildtype
mice, which may not occur under physiological conditions. The
60-fold increase in expression may interfere with the CREB
signaling pathway and homeostatic regulation of CREB.
Figure 3. CREB expression and phosphorylation in the CPu
after single and repeated METH treatment. The mice were
administered METH (1 mg/kg, i.p.) or saline once or received METH
(1 mg/kg, i.p.) once every other day from Day 1 to Day 13 and
challenged with saline or METH (1 mg/kg, i.p.) on Day 20 after a 7 day
drug-free period. The mice were decapitated 1 h after the last METH or
saline treatment. The blot density of each group was normalized to that
of the wildtype saline group and is expressed as mean 6 SEM (n=6). a.
METH-induced CREB expression in the CPu in wildtype mice (WT) and
ICER I-overexpressing mice (Tg). *p,0.05, significant difference in
normalized CREB blot density compared with wildtype saline group. b.
METH-induced CREB phosphorylation in the CPu in wildtype mice (WT)
and ICER I-overexpressing mice (Tg). *p,0.05, significant difference in
normalized pCREB blot density compared with wildtype saline group.
doi:10.1371/journal.pone.0021637.g003
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mRNA expression
CART and dynorphin are peptidergic neurotransmitters
expressed in the CPu and other brain regions and modulate the
rewarding effects of drugs of abuse [17,26,36]. CART’s involve-
ment in the actions of psychostimulants was first noted in a study
that demonstrate that acute cocaine and amphetamine upregu-
lated CART mRNA in the rat brain [37]. However, this report
has been controversial because this finding has been difficult to
replicate [38–40]. Other studies found that binge cocaine
exposure, rather than acute administration, reliably increases
CART expression [38,41]. Additionally, Pdyn mRNA has been
reported to increase or not change in response to binge cocaine
administration [42,43]. In the present study, neither acute nor
repeated administration of METH (1 mg/kg) altered CART and
Pdyn mRNA expression in wildtype mice. Furthermore, METH
administration (1 mg/kg) did not alter ICER mRNA expression in
wildtype mice. A possible reason for this might be that the 1 mg/
kg dose of METH may not have been sufficient to induce
detectable alterations of ICER, CART, and Pdyn mRNA.
However, CART and Pdyn mRNA expression levels significantly
decreased as ICER mRNA levels significantly increased, suggest-
ing an inhibitory role of ICER in CART and Pdyn expression.
Both the CART and Pdyn genes contain a CRE site in their
promoter regions [21–22], and CART and Pdyn mRNA levels are
regulated by CREB in vitro [21,44] and in vivo [8,23]. Therefore, as
a CRE-mediated gene transcription repressor, ICER may inhibit
the expression of CART and Pdyn in vivo. Our studies using ICER
I-overexpressing mice support this hypothesis.
CART and Pdyn as neuromodulators of the behavioral
effects of psychostimulants
The CART and Pdyn peptides are neurotransmitters expressed
in brain regions associated with drug reward, including the NAc
and VTA [16–17]. Numerous studies have suggested that CART
and Pdyn play a homeostatic role in the NAc to oppose the effects
of cocaine. For example, pretreatment with Dyn A (1–17) is
effective at decreasing striatal dopamine levels and attenuating
Figure 4. ICER, CART, and Pdyn mRNA levels in the CPu after single and repeated METH treatment. The mice were administered METH
(1 mg/kg, i.p.) or saline once or received METH (1 mg/kg, i.p.) once every other day from Day 1 to Day 13 and challenged with saline or METH (1 mg/
kg, i.p.) on Day 20 after a 7 day drug-free period. The mice were decapitated 1 h after the last METH or saline treatment. a. ICER mRNA expression in
the CPu in wildtype (WT) and ICER I-overexpressing (Tg) mice. The data are expressed as mean 6 SEM (n=4). b. CART mRNA expression in the CPu
after single and repeated METH treatment. The data are expressed as mean 6 SEM (n=4). c. Pdyn mRNA expression in the CPu after single and
repeated METH treatment. The data are expressed as mean 6 SEM (n=4).
doi:10.1371/journal.pone.0021637.g004
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resulting increases in Pdyn gene expression, in the NAc has been
shown to decrease the rewarding effects of cocaine [8].
Microinjection of CART peptide 55–102 into the NAc blocked
the rewarding effects of cocaine and amphetamine [46–48].
CREB overexpression increases CART mRNA levels in the NAc
and decreases the rewarding effects of drugs [23]. However,
studies in knockout mice have reported conflicting results. CART
knockout mice exhibited attenuated locomotor sensitization
induced by amphetamine [18], and Pdyn knockout mice showed
decreased locomotor activity evoked by cocaine [30]. ICER I-
overexpressing mice with decreased CART and Pdyn expression
levels displayed attenuated METH-induced locomotor sensitiza-
tion in the present study. These discrepant results among CART
and Pdyn studies may be attributable to differences between
systemic and NAc-specific downregulation of CART or Pdyn.
Further studies are needed to clarify the effects of CART and Pdyn
in brain regions other than the NAc.
Conclusion
The present study suggests that ICER plays an inhibitory role in
METH-induced locomotor sensitization. Our results support the
modulatory effects of the ICER pathway in regulating the effects of
drugs of abuse and provide an incentive for exploring the
therapeutic potential of stimulating the ICER pathway in the
treatment of drug abuse.
Materials and Methods
Ethics statement
The experimental procedures and housing conditions were
approved by the Institutional Animal Care and Use Committee
(Animal Experimentation Ethics Committee of Tokyo Metropol-
itan Institute of Medical Science, Approval ID: 11-029), and all
animals were cared for and treated humanely in accordance with
our institutional animal experimentation guidelines.
Animals
Wildtype, ICER knockout, and ICER I-overexpressing mice
were produced by conventional gene targeting and transgenic
methods [24]. Briefly, the P2 exon encoding the 59 coding sequence
of ICER was deleted to generate ICER-specific knockout mice. To
generate ICER I-overexpressing mice,theentire codingsequenceof
cDNA was subcloned into a pNN265 vector, and the promoter for
Ca
2+/calmodulin-dependent protein kinase II a (CaMKIIa)w a s
used to express ICER I in the forebrain. The expression patterns of
other CREB/CREM family members are not altered in either
ICER knockout mice or ICER I-overexpressing mice. ICER
knockout mice and their littermates were produced by heterozy-
gote-heterozygote mating. ICER I-overexpressing mice and their
wildtype littermates were produced by mating ICER I-overexpress-
ing mice (line I-19) and C57BL/6 mice (CLEA Japan Inc.,
Shizuoka, Japan) because C57BL/6 is the genetic background
strain of ICER I-overexpressing mice. Only naive male mice were
used for the experiments. The mice were housed five per cage in a
temperature- (2262uC) and humidity-controlled (5565%) environ-
ment on a 12 h/12 h light/dark cycle (lights on 8:00 a.m. to 8:00
p.m.). The mice had ad libitum access to a standard laboratory diet
and water. All animal experiments were conducted during the light
phase of the cycle, between 9:00 a.m. and 5:00 p.m.
Drugs
Methamphetamine hydrochloride (Dainippon-Sumitomo Phar-
maceuticals, Osaka, Japan) was dissolved in saline (0.9% sodium
chloride) and administered intraperitoneally (i.p.) in a volume of
10 ml/kg.
Locomotor activity
Locomotor activity corresponding to distance travelled was
evaluated in a test chamber (25 cm diameter, 27 cm height) and
measured in 5 min bins using digital counters with passive infrared
sensors (Supermex system, Muromachi Kikai, Tokyo, Japan).
Wildtype littermates of ICER knockout mice (n=13), ICER
knockout mice (n=13), wildtype littermates of ICER I-overex-
pressing mice (n=7), and ICER I-overexpressing mice (n=9) were
used. The mice were first habituated to the apparatus for 180 min
and then injected with METH (1 mg/kg, i.p.). Locomotor activity
was then measured for 60 min after the injection. The procedure
was repeated seven times, once every other day from Day 1 to Day
13. After a 7 day drug-free period, locomotor activity was
measured again after an injection of METH (1 mg/kg, i.p.) on
Day 20.
Western blot analysis
The experiment involved four groups of ICER I-overexpressing
mice and wildtype mice: Saline, Single METH, Repeated
METH/Saline Challenge, and Repeated METH/METH Chal-
lenge. Saline and METH (1 mg/kg, i.p.) were administered once
to Saline and Single METH mice, respectively, and the mice were
decapitated 1 h after the injection. The Repeated METH/Saline
Challenge and Repeated METH/METH Challenge groups
received METH (1 mg/kg, i.p.) once every other day from Day
1 to Day 13 and were challenged with saline and METH (1 mg/
kg, i.p.), respectively, on Day 20 after a 7 day drug-free period.
The mice were decapitated 1 h after the last METH or saline
treatment. The brains were removed in less than 45 s and cooled
rapidly in ice-cold saline for 30 s. The CPu was then dissected.
The tissue was quickly frozen on dry ice, stored at 280uC, and
homogenized in 100 ml phosphate-buffered saline containing
protease inhibitors (Roche Applied Science, Mannheim, Ger-
many) and PhosStop phosphatase inhibitors (Roche Applied
Science, Mannheim, Germany). The homogenate was diluted to
4 mg/ml with 26Laemmli buffer, heated to 95uC for 2 min, and
loaded (20 mg of protein) onto 5–20% gradient polyacrylamide
gels. The proteins from eight groups were loaded onto the same
gel and separated at 50 mA for approximately 1 h and then
transferred onto polyvinylidene membranes in a semi-dry blotter.
Nonspecific protein binding sites were blocked by incubating in
Blocking One Solution (Nakalai Tesque Inc., Kyoto, Japan). The
membranes were incubated overnight at 4uC with phosphor
(Ser133) CREB (pCREB) antibody (1:2000; Millipore, Billerica,
MA, USA). After incubation in secondary antibody (horseradish
peroxidase-conjugated goat antibody to rabbit, 1:50,000; Zymed
Labs, South San Francisco, CA, USA) for 1 h, the membrane was
treated with chemiluminescent substrate (Millipore, Billerica, MA,
USA) and visualized by exposure to Hyperfilm electrochemilumi-
nescence film (GE Healthcare Bio-Sciences, Tokyo, Japan).
pCREB blots were stripped with 10% acetic acid solution for
15 min at room temperature. The membranes were reprobed for
CREB antibody (1:2000; Cell Signaling Technology, Tokyo,
Japan). Finally, the blots were stripped and reprobed for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody
(1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
blots were quantified using ImageJ software (National Institutes of
Health, Bethesda, MD, USA), and the sizes were compared with
prestained molecular-weight standards. Individual CREB and
pCREB values were divided by their respective sample GAPDH
values to obtain CREB/GAPDH and pCREB/GAPDH ratio
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GAPDH ratio values from the wildtype saline group were
averaged, and the mean was used as a control value. Therefore,
the CREB/GAPDH and pCREB/GAPDH ratio values of each
sample were calculated as a percentage of this control.
Quantitative real-time reverse transcription polymerase
chain reaction
The experiment involved four groups of ICER I-overexpressing
mice and wildtype mice: Saline, Single METH, Repeated
METH/Saline Challenge, and Repeated METH/METH Chal-
lenge. The saline and METH treatments, euthanasia, brain
dissection, and storage of brain tissues were the same as described
above for Western blot. Total RNA was isolated using Trizol
reagent (Invitrogen Life Technology, Tokyo, Japan) and converted
into cDNA using a SuperScript VILO cDNA Synthesis Kit
(Invitrogen Life Technology, Tokyo, Japan). The real-time RT-
PCR reaction was conducted using a LightCycler 480 Instrument
(Roche Applied Science, Mannheim, Germany). The ICER,
CART, Pdyn, and b-actin primers for real-time RT-PCR were the
following: ICER (59-GCTGAGGCTGATGAAAAACA-39 and
59-GCCACACGATTTTCAAGACA-39), CART (59-CGAGAA-
GAAGTACGGCCAAG-39 and 59-CACACAGCTTCCCGAT-
CC-39), Pdyn (59-TTATGGCGGACTGCCTGT-39 and 59-
CACTCCAGGGAGCAAATCAG39), and b-actin (59-CTAAG-
GCCAACCGTGAAAAG-39 and 59-ACCAGAGGCATACAG-
GACA-39). Universal Probes #4, #108, #99, and #64 (Roche
Applied Science, Mannheim, Germany) were used for ICER,
CART, Pdyn, and b-actin, respectively. Amplification consisted of
a preincubation step (95uC for 10 min), 45 cycles of denaturation
for 10 s at 95uC, and annealing for 30 s at 60uC. Amplification
curves were produced to calculate the crossing point at which the
fluorescence of a sample rises above the initial lag phase. Absolute
quantification analysis was performed using LightCycler 480
software (Roche Applied Science, Mannheim, Germany). Serial
dilutions of an external standard with a predefined, known
concentration were used to create a standard curve. The standard
dilutions were amplified in separate wells but within the same
instrument as the target samples. The crossing points of standards
and unknown samples were then used to determine the
concentration of the target mRNA. ICER, CART, and Pdyn
mRNA levels were normalized according to b-actin mRNA levels.
The ICER/b-actin, CART/b-actin, and Pdyn/b-actin values
from the wildtype saline group were averaged, and the mean
was used as a control value. Therefore, the relative expression
levels of CART and Pdyn were calculated as a percentage of this
control.
Statistical analysis
The data are expressed as mean 6 SEM. The data for the
Western blot, real-time RT-PCR, and locomotor sensitization
experiments were analyzed by two-way, mixed-design ANOVA
and repeated-measures ANOVA followed by the Dunnett post hoc
test (for the Western blot analysis and real-time RT-PCR
experiments) or Tukey-Kramer post hoc test (for the locomotor
sensitization experiment). Values of p,0.05 were considered
statistically significant.
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